Aktiesnakken — Marts 2010
-
hvis man var optimistisk anlagt begyndte man at kigge lidt på erbitux tallene
-
hvad var median leve tiden for dem, solsen?
-
på en igen
-
altså erbitux?
-
det handler om "placebo" justerede effekt.hvorfor en direkte sammenligning ik kan fortages
-
og BSC armen har formentligt ikke fået den samme behandling i dag som for hmm 5 år? siden da erbitux var gennem forsøget
-
det var også mere for at åbne op for den mulighed at det måske ikke er så skidt som man tro
-
nogen der kan finde slides på deres website?
-
jeg har vente musik nu
-
også her aka. Men der er ingen slidesw i webcastet
-
det ermærkeligt at zalutumumab alene giver bedre performance
-
hvorfor fanden fremhæver de ikke det?
-
zalut alene møder jo endpoint?
-
However, patients in the zalutumumab arm did experience a 61% increase in progression free survival compared to patients in the BSC alone ar
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind